Technology | Treatment Planning | May 02, 2016

Elekta Debuts Monaco 5.11 Treatment Planning Software at ESTRO 35

Latest version features up to four times faster calculation spped for reduced radiotherapy planning times

Elekta, ESTRO 35, Monaco treatment planning system, radiotherapy, version 5.11

May 2, 2016 — Elekta announced that Monaco version 5.11, the latest update to its treatment planning software, is available for clinical release.

Real-world testing has shown that Monaco version 5.11 provides significant performance speed enhancements over prior versions. Users can now attain calculation speeds up to four times faster than in previous versions of Monaco. With the Monte Carlo algorithm, users can achieve robust accuracy combined with speed and performance.

Fast plan calculation time is just one of the many characteristics in Monaco designed to improve overall efficiency. Monaco templates enable users to easily import and export treatment plans, facilitating sharing across departments and organizations. With the ability to create multiple prescription plans at one time, overall planning time is reduced. Additionally, improved data sharing creates additional opportunities to optimize individual treatment plans to meet the needs of each patient.

“The optimization speed enhancements in version 5.11, combined with previous innovations, such as template planning, provide substantial improvements in planning workflow efficiencies, while continuing to deliver highly accurate treatment plans using Monte Carlo dose calculations,” said Sotiri Stathakis, Ph.D., associate professor, radiation oncology and radiology at University of Texas Health Science Center in San Antonio, Texas. “We have been testing Monaco version 5.11 for several months and, so far, we have seen up to 3-4 times reduction in the optimization of VMAT [volumetric modulated arc therapy] plans equivalent to a 70 percent reduction in optimization times.”

Monaco was one of several innovations highlighted during the 2016 meeting of the European Society for Therapeutic Radiation & Oncology (ESTRO 35), April 29-May 3 in Turin, Italy.

For more information: www.elekta.com

Related Content

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | March 19, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.